Double-blind, randomised, placebo-controlled trial of allergen-specific immunotherapy with major allergen Alt a 1.

Ana Isabel Tabar,Luis Prieto,Pilar Alba,Antonio Nieto,Mercedes Rodríguez, Miguel Torrecillas, Beatriz Huertas,Elisa Gómez,Francisco Javier Fernández,Miguel Blanca,David Rodríguez,Ricardo Palacios

Journal of Allergy and Clinical Immunology（2019）

引用 29|浏览14

暂无评分

摘要

Immunotherapy with Alt a 1 was efficacious and safe, reducing the symptoms and medication associated with rhinoconjunctivitis after only one year of treatment. The clinical benefits were associated with reduced skin reactivity and specific IgE, and increased IgG.

查看译文

关键词

Allergen immunotherapy,clinical trial,Alt a 1,molecular immunotherapy,rhinoconjunctivitis,efficacy,safety,fungal allergy,subcutaneous immunotherapy,purified allergen,adults,children

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要